Quarterly report [Sections 13 or 15(d)]

Revenues from Contracts and Significant Customers (Tables)

v3.25.1
Revenues from Contracts and Significant Customers (Tables)
3 Months Ended
Mar. 31, 2025
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

The table below summarizes the Company’s net revenue for the periods presented:

Three Months Ended March 31, 

($ in thousands)

    

2025

    

2024

Qbrexza

$

5,161

$

5,017

Accutane

3,655

5,819

Emrosi

2,070

Amzeeq

1,100

755

Zilxi

426

273

Other / legacy product revenue

727

1,166

Total net revenue

$

13,139

$

13,030